Baidu
map

北京推出跨境电商销售医药产品试点工作实施方案

2020-01-01 林苗苗 新华网

记者从北京市药监局获悉,北京市药监局会同北京市商务局、北京海关、北京天竺综合保税区管理委员会制定的《北京市跨境电商销售医药产品试点工作实施方案》于2019年12月30日发布,这是国内跨境电商政策在涉及医药产品方面的一次“破冰”。 据介绍,试点品种是在境内已经注册上市的,以及财政部等十三部委联合发布的清单内产品,主要为家用日常药品和医疗器械品种。试点企业需具备符合开展试点要求的电子商务平台

记者从北京市药监局获悉,北京市药监局会同北京市商务局、北京海关、北京天竺综合保税区管理委员会制定的《北京市跨境电商销售医药产品试点工作实施方案》于2019年12月30日发布,这是国内跨境电商政策在涉及医药产品方面的一次“破冰”。
 
据介绍,试点品种是在境内已经注册上市的,以及财政部等十三部委联合发布的清单内产品,主要为家用日常药品和医疗器械品种。试点企业需具备符合开展试点要求的电子商务平台交易服务系统,实现对跨境医药产品的质量管控、追溯管理,并建立完善的跨境医药产品风险防控体系、售前售中售后服务体系和质量保障体系。

根据方案,试点企业负有追溯义务,应当以“一物一码、物码同追”为基本原则建立跨境医药产品追溯体系,充分发挥企业的主体作用,实现跨境医药产品境内最小包装单元可追溯、可核查。鼓励试点企业将跨境医药产品境外生产流通环节纳入追溯体系。鼓励试点企业建立跨境医药产品先行赔付制度。

方案要求,试点企业应当是注册在北京市行政区域内、具备企业法人和医疗器械网络交易服务第三方平台资格的企业,相关跨境医药产品应当在北京口岸通关,并在天竺综保区内具有符合跨境医药产品存储要求的仓储能力(可以委托符合条件的物流仓储企业)。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2079496, encodeId=3cff20e949609, content=<a href='/topic/show?id=5fe6352e00a' target=_blank style='color:#2F92EE;'>#医药产品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35270, encryptionId=5fe6352e00a, topicName=医药产品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jul 31 16:35:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043561, encodeId=2d92204356177, content=<a href='/topic/show?id=167046042c8' target=_blank style='color:#2F92EE;'>#实施方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46042, encryptionId=167046042c8, topicName=实施方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2bcd469, createdName=fengting3, createdTime=Thu Jul 16 06:35:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641764, encodeId=3aa61641e64e7, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Sat May 16 05:35:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813100, encodeId=09d018131007d, content=<a href='/topic/show?id=4b3f91e482a' target=_blank style='color:#2F92EE;'>#试点工作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91748, encryptionId=4b3f91e482a, topicName=试点工作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Sat May 23 18:35:00 CST 2020, time=2020-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687362, encodeId=3d27168e362c7, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Mon Nov 30 01:35:00 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409968, encodeId=4ac9140996880, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Jan 03 12:35:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2079496, encodeId=3cff20e949609, content=<a href='/topic/show?id=5fe6352e00a' target=_blank style='color:#2F92EE;'>#医药产品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35270, encryptionId=5fe6352e00a, topicName=医药产品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jul 31 16:35:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043561, encodeId=2d92204356177, content=<a href='/topic/show?id=167046042c8' target=_blank style='color:#2F92EE;'>#实施方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46042, encryptionId=167046042c8, topicName=实施方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2bcd469, createdName=fengting3, createdTime=Thu Jul 16 06:35:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641764, encodeId=3aa61641e64e7, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Sat May 16 05:35:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813100, encodeId=09d018131007d, content=<a href='/topic/show?id=4b3f91e482a' target=_blank style='color:#2F92EE;'>#试点工作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91748, encryptionId=4b3f91e482a, topicName=试点工作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Sat May 23 18:35:00 CST 2020, time=2020-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687362, encodeId=3d27168e362c7, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Mon Nov 30 01:35:00 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409968, encodeId=4ac9140996880, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Jan 03 12:35:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2079496, encodeId=3cff20e949609, content=<a href='/topic/show?id=5fe6352e00a' target=_blank style='color:#2F92EE;'>#医药产品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35270, encryptionId=5fe6352e00a, topicName=医药产品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jul 31 16:35:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043561, encodeId=2d92204356177, content=<a href='/topic/show?id=167046042c8' target=_blank style='color:#2F92EE;'>#实施方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46042, encryptionId=167046042c8, topicName=实施方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2bcd469, createdName=fengting3, createdTime=Thu Jul 16 06:35:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641764, encodeId=3aa61641e64e7, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Sat May 16 05:35:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813100, encodeId=09d018131007d, content=<a href='/topic/show?id=4b3f91e482a' target=_blank style='color:#2F92EE;'>#试点工作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91748, encryptionId=4b3f91e482a, topicName=试点工作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Sat May 23 18:35:00 CST 2020, time=2020-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687362, encodeId=3d27168e362c7, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Mon Nov 30 01:35:00 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409968, encodeId=4ac9140996880, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Jan 03 12:35:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2079496, encodeId=3cff20e949609, content=<a href='/topic/show?id=5fe6352e00a' target=_blank style='color:#2F92EE;'>#医药产品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35270, encryptionId=5fe6352e00a, topicName=医药产品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jul 31 16:35:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043561, encodeId=2d92204356177, content=<a href='/topic/show?id=167046042c8' target=_blank style='color:#2F92EE;'>#实施方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46042, encryptionId=167046042c8, topicName=实施方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2bcd469, createdName=fengting3, createdTime=Thu Jul 16 06:35:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641764, encodeId=3aa61641e64e7, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Sat May 16 05:35:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813100, encodeId=09d018131007d, content=<a href='/topic/show?id=4b3f91e482a' target=_blank style='color:#2F92EE;'>#试点工作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91748, encryptionId=4b3f91e482a, topicName=试点工作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Sat May 23 18:35:00 CST 2020, time=2020-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687362, encodeId=3d27168e362c7, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Mon Nov 30 01:35:00 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409968, encodeId=4ac9140996880, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Jan 03 12:35:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2079496, encodeId=3cff20e949609, content=<a href='/topic/show?id=5fe6352e00a' target=_blank style='color:#2F92EE;'>#医药产品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35270, encryptionId=5fe6352e00a, topicName=医药产品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jul 31 16:35:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043561, encodeId=2d92204356177, content=<a href='/topic/show?id=167046042c8' target=_blank style='color:#2F92EE;'>#实施方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46042, encryptionId=167046042c8, topicName=实施方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2bcd469, createdName=fengting3, createdTime=Thu Jul 16 06:35:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641764, encodeId=3aa61641e64e7, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Sat May 16 05:35:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813100, encodeId=09d018131007d, content=<a href='/topic/show?id=4b3f91e482a' target=_blank style='color:#2F92EE;'>#试点工作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91748, encryptionId=4b3f91e482a, topicName=试点工作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Sat May 23 18:35:00 CST 2020, time=2020-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687362, encodeId=3d27168e362c7, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Mon Nov 30 01:35:00 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409968, encodeId=4ac9140996880, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Jan 03 12:35:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2079496, encodeId=3cff20e949609, content=<a href='/topic/show?id=5fe6352e00a' target=_blank style='color:#2F92EE;'>#医药产品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35270, encryptionId=5fe6352e00a, topicName=医药产品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jul 31 16:35:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043561, encodeId=2d92204356177, content=<a href='/topic/show?id=167046042c8' target=_blank style='color:#2F92EE;'>#实施方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46042, encryptionId=167046042c8, topicName=实施方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2bcd469, createdName=fengting3, createdTime=Thu Jul 16 06:35:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641764, encodeId=3aa61641e64e7, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Sat May 16 05:35:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813100, encodeId=09d018131007d, content=<a href='/topic/show?id=4b3f91e482a' target=_blank style='color:#2F92EE;'>#试点工作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91748, encryptionId=4b3f91e482a, topicName=试点工作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Sat May 23 18:35:00 CST 2020, time=2020-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687362, encodeId=3d27168e362c7, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Mon Nov 30 01:35:00 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409968, encodeId=4ac9140996880, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Jan 03 12:35:00 CST 2020, time=2020-01-03, status=1, ipAttribution=)]
    2020-01-03 cathymary

相关资讯

重磅!北京十三五医改实施方案出台

最近,市医改办在忙活一件大事~发改君先带大家看一组数据——到2017年底,家庭医生重点人群签约服务覆盖率力争达到90%以上;按病种分组付费的病组数达到300组以上;公立医院药占比(不含中药饮片)总体降到30%左右;百元医疗收入(不含药品收入)中消耗的卫生材料将到20元以下……到2020年,按病种分组付费方式将覆盖全部病组,个人卫生支出占卫生总费用的比重保持在20%左右,每万名居民拥有3名以上全科医

新格局!**医疗中心实施方案出炉

1月24日,《国家医学中心和国家区域医疗中心设置实施方案》(以下简称《实施方案》)终于由国家卫生健康委办公厅以国卫办医函〔2019〕45号印发并挂在国家卫健委官网上。

黑龙江省政府发布实施方案:鼓励社会办中医诊所做大做强

近日,《黑龙江省支持社会力量提供多层次多样化医疗服务发展健康产业实施方案》由省政府发布,明确要求放宽市场准入,对社会资本举办的包括中医、中西医结合等在内的各级各类医疗机构,实行市场调节的管理方式,取消数量、地点、床位和大型设备等资源配置的限制。

Baidu
map
Baidu
map
Baidu
map